Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/31/2025

Effects of Steroids on the Clotting Cascade

Corticosteroids

  • Corticosteroids have minimal direct effects on the clotting cascade, with no significant evidence showing they increase thrombotic risk when used alone 1
  • Four small randomized trials of corticosteroids for intracerebral hemorrhage showed no benefit, and one study demonstrated increased risk of infectious complications with steroid use 1
  • In immune thrombocytopenia treatment guidelines, corticosteroids are noted to have side effects but these are generally less pronounced with short courses (<7 days) used to treat children 2, 3
  • When used in post-liver transplant settings, corticosteroids can contribute to metabolic syndrome components including diabetes, weight gain, and hepatic steatosis, which may indirectly increase thrombotic risk 4

Sex Hormones (Estrogen and Progesterone)

  • Combined estrogen and progesterone therapy significantly increases thrombotic risk by 2-3 fold compared to non-users 5
  • Meta-analyses demonstrate that hormone replacement therapy more than doubles the risk of venous thromboembolism (RR 2.14; 95% CI 1.64-2.81) 5
  • The Women's Health Initiative study confirmed a two-fold increased rate of venous thromboembolic disease (RH 2.11; 95% CI 1.26-3.55) in women taking combined estrogen-progestin therapy 5
  • Estrogen affects multiple hemostatic pathways in a prothrombotic direction by increasing factor VII activity, D-dimer, and prothrombin F1.2, and decreasing anti-thrombin III, tissue factor pathway inhibitor, and tissue plasminogen activator 6, 5
  • The thrombogenic effect of estrogen is amplified when co-administered with other medications, including chemotherapy and steroids 7

Steroids in Cancer Patients and Thrombotic Risk

  • In cancer patients, steroids may contribute to thrombotic risk when combined with other medications 7
  • The thrombogenic effect of antiangiogenic agents (bevacizumab, thalidomide, lenalidomide) is amplified by co-administration of chemotherapy and steroids 7
  • For multiple myeloma patients receiving immunomodulatory drugs (lenalidomide, thalidomide, pomalidomide), guidelines note an increased risk of bleeding in patients on aspirin who are also receiving steroids 8
  • Prothrombotic genetic variants significantly increase thrombosis risk with hormone therapy 6, 5
  • Factor V Leiden carriers taking hormone therapy have significantly increased risk of venous thromboembolism compared to non-carriers taking placebo 6
  • Similar increased risk is seen with the prothrombin 20210A variant in women using hormone therapy 6

Clinical Implications

  • The risk-benefit profile of steroid therapy should be carefully evaluated, particularly in patients with additional thrombotic risk factors 5
  • For sex hormone therapy, the U.S. Preventive Services Task Force concluded there is good evidence that hormone replacement therapy increases the risk for venous thromboembolism 5

Thromboprophylaxis for Patients Receiving High‑Dose Intravenous Corticosteroids in Acute Severe Ulcerative Colitis

Clinical Recommendation

  • Hospitalized patients with acute severe ulcerative colitis who are treated with high‑dose intravenous corticosteroids (e.g., methylprednisolone 60 mg daily or hydrocortisone 100 mg every 6 hours) have a 2–3‑fold increased risk of venous thromboembolism and should receive prophylactic low‑molecular‑weight heparin during the steroid course. 9